Table 1.
Baseline clinical, biochemical and pathological features of the cohort
| Parameters | Value |
|---|---|
| Clinical: | |
| Cohort total number of patients: | 1425 |
| Age at diagnosis, years, mean (SD): | 68.6 (8.72) |
| Age categories, n (%) | |
| - < 50 years | 8 (0.6%) |
| - 50–74 years | 861 (60.4%) |
| - ≥75 years | 556 (39%) |
| Baseline prostate volume (ml3), median [IQR]: | 36.4 [27–49.8] |
| Clinical stage: n (%) | |
| - T1-2a | 859 (60.3%) |
| - T2b | 355 (24.9%) |
| - T2c-3a | 211 (14.8%) |
| Biochemical: | |
| Baseline PSA (ng/ml), median [IQR] | 7.55 [5.4–12] |
| PSA categories, ng/ml, n (%) | |
| - ≤ 4: | 113 (7.9%) |
| - 4.1–10: | 835 (58.6%) |
| - 10.1–20: | 293 (20.6%) |
| - > 20 | 184 (12.9%) |
| PSA density (ng/ml/ml3), median [IQR] | 0.21 [0.13–0.36] |
| Pathological: | |
| Gleason score, n (%) | |
| - Gleason ≤6: | 566 (39.7%) |
| - Gleason 7: | 473 (33.2%) |
| - Gleason 8: | 194 (13.6%) |
| - Gleason 9: | 168 (11.8%) |
| - Gleason 10: | 24 (1.7%) |
| D’Amico risk classification, n (%) | |
| - Low: | 477 (33.4%) |
| - Intermediate: | 503 (35.3%) |
| - High | 445 (31.2%) |
SD Standard Deviation, IQR Inter Quartile Range, n (%): Number of patients (Percentage)